Abstract
The lack of biomimetic in vitro models of the human heart has posed a critical barrier to progress in the field of modeling cardiac disease. Human engineered cardiac tissues (hECTs)—autonomous, beating structures that recapitulate key aspects of native cardiac muscle physiology—offer an attractive alternative to traditional in vitro models. Here we describe the use of hECTs to advance our understanding and modeling of cardiac diseases in order to test therapeutic interventions, with a focus on contractile dysfunction in the setting of inherited and acquired forms of cardiomyopathies. Four major procedures are discussed in this chapter: (1) preparation of hECTs from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) on single-tissue and multitissue bioreactors; (2) data acquisition of hECT contractile function on both of these platforms; (3) hECT modeling of hereditary phospholamban-R14 deletion-dilated cardiomyopathy; and (4) cryo-injury and doxorubicin-induced hECT models of acquired cardiomyopathy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, Canter C, Wilkinson JD, Lipshultz SE (2006) Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296(15):1867–1876. https://doi.org/10.1001/jama.296.15.1867
Mushtaq M, DiFede DL, Golpanian S, Khan A, Gomes SA, Mendizabal A, Heldman AW, Hare JM (2014) Rationale and design of the percutaneous stem cell injection delivery effects on neomyogenesis in dilated cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. J Cardiovasc Transl Res 7(9):769–780. https://doi.org/10.1007/s12265-014-9594-0
Turnbull IC, Karakikes I, Serrao GW, Backeris P, Lee JJ, Xie C, Senyei G, Gordon RE, Li RA, Akar FG, Hajjar RJ, Hulot JS, Costa KD (2014) Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB J 28(2):644–654. https://doi.org/10.1096/fj.13-228007
Mayourian J, Ceholski DK, Gonzalez DM, Cashman TJ, Sahoo S, Hajjar RJ, Costa KD (2018) Physiologic, pathologic, and therapeutic paracrine modulation of cardiac excitation-contraction coupling. Circ Res 122(1):167–183
Mayourian J, Cashman TJ, Ceholski DK, Johnson BV, Sachs D, Kaji DA, Sahoo S, Hare JM, Hajjar RJ, Sobie EA, Costa KD (2017) Experimental and computational insight into human mesenchymal stem cell paracrine signaling and heterocellular coupling effects on cardiac contractility and arrhythmogenicity. Circ Res 121(4):411–423. https://doi.org/10.1161/CIRCRESAHA.117.310796
Serrao GW, Turnbull IC, Ancukiewicz D, Kim DE, Kao E, Cashman TJ, Hadri L, Hajjar RJ, Costa KD (2012) Myocyte-depleted engineered cardiac tissues support therapeutic potential of mesenchymal stem cells. Tissue Eng Part A 18(13–14):1322–1333. https://doi.org/10.1089/ten.TEA.2011.0278
Stillitano F, Turnbull IC, Karakikes I, Nonnenmacher M, Backeris P, Hulot JS, Kranias EG, Hajjar RJ, Costa KD (2016) Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. Eur Heart J 37(43):3282–3284. https://doi.org/10.1093/eurheartj/ehw307
Strungs EG, Ongstad EL, O’Quinn MP, Palatinus JA, Jourdan LJ, Gourdie RG (2013) Cryoinjury models of the adult and neonatal mouse heart for studies of scarring and regeneration. Methods Mol Biol 1037:343–353. https://doi.org/10.1007/978-1-62703-505-7_20
Toyoda Y, Okada M, Kashem MA (1998) A canine model of dilated cardiomyopathy induced by repetitive intracoronary doxorubicin administration. J Thorac Cardiovasc Surg 115(6):1367–1373. https://doi.org/10.1016/S0022-5223(98)70221-1
Karakikes I, Senyei GD, Hansen J, Kong CW, Azeloglu EU, Stillitano F, Lieu DK, Wang J, Ren L, Hulot JS, Iyengar R, Li RA, Hajjar RJ (2014) Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes. Stem Cells Transl Med 3(1):18–31. https://doi.org/10.5966/sctm.2013-0110
Cashman TJ, Josowitz R, Gelb BD, Li RA, Dubois NC, Costa KD (2016) Construction of defined human engineered cardiac tissues to study mechanisms of cardiac cell therapy. J Vis Exp 109:e53447. https://doi.org/10.3791/53447
Acknowledgments
This work was supported by NIH/NHLBI K01HL133424 (ICT), NIH/NHLBI 1F30HL134283-01A1 (JM), American Heart Association 15POST25090116 (DKC), and NIH/NHLBI R01HL132226 (KDC).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Turnbull, I.C., Mayourian, J., Murphy, J.F., Stillitano, F., Ceholski, D.K., Costa, K.D. (2018). Cardiac Tissue Engineering Models of Inherited and Acquired Cardiomyopathies. In: Ishikawa, K. (eds) Experimental Models of Cardiovascular Diseases. Methods in Molecular Biology, vol 1816. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8597-5_11
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8597-5_11
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8596-8
Online ISBN: 978-1-4939-8597-5
eBook Packages: Springer Protocols